Download PDF
Seminars in Neurosurgery 2001; 12(3): 305-314
DOI: 10.1055/s-2001-33621
Copyright © 2002 by Thieme Medical Publishers, Inc., 333 Seventh Avenue, New York, NY 10001, USA. Tel.: +1(212) 584-4662

Management of Cushing's Disease: An Update

Kalmon D. Post, Kevin Yao, Jane Walsh
  • Department of Neurosurgery, Mount Sinai Medical Center, New York, New York
Further Information

Publication History

Publication Date:
27 August 2002 (online)

    Permissions and Reprints

ABSTRACT

Most cases of hypercortisolemia seen in the adult population are caused by microadenomas of the anterior pituitary gland.[1] [19] Cushing's disease is the life-shortening illness caused by hypercortisolism secondary to an adrenocorticotropic hormone (ACTH)-secreting pituitary adenoma. More than any other secretory tumor of the pituitary gland, the basophilic ACTH-producing adenoma responsible for Cushing's disease continues to provide the clinician with diagnostic and therapeutic challenges. Recent advances in surgical strategy, endocrinologic assessment, and adjuvant therapies have improved the surgeon's ability to treat this medically devastating disease.

The distinction between primary (adrenal) and secondary [pituitary ACTH or ectopic ACTH and/or corticotropin-releasing hormone (CRH) excess] hypercortisolemia is based upon the absence or presence of a measurable ACTH level. Establishing the presence of Cushing's syndrome with elevated serum cortisols and 24-hour urinary-free cortisols is mandatory before proceeding with further testing.

Bilateral simultaneous sampling of blood from the inferior petrosal sinuses for ACTH measurement provides additional information that may be important for the diagnosis or management of some patients with ACTH-dependent Cushing's (i.e., either pituitary or ectopic ACTH overproduction). In our algorithm, petrosal sinus blood collection and sampling for ACTH after CRH stimulation are performed in all patients with Cushing's syndrome and normal or questionable magnetic resonance imaging (MRI). If the initial or dynamic MRI confirms an abnormality suggestive of an adenoma, and the endocrine data are secure, we do not do petrosal sampling. In our experience, even with modern MRI, including rapid sequence studies, 45% of patients with Cushing's disease have normal MRI studies.

The treatment of choice for Cushing's disease is transsphenoidal exploration of the pituitary gland, with selective adenomectomy, although results thus far have been less than perfect. For those with very large or invasive tumors, we perform surgery for diagnosis and debulking, followed by conventional radiation therapy, stereotactic radiotherapy or radiosurgery, medications, and, occasionally, adrenalectomy. Outcomes do not correlate with the presence of a lesion on preoperative imaging or histology-documented tumor.

``Cure'' in the setting of Cushing's disease is defined as remission of clinical symptoms secondary to hypercortisolemia, biochemical confirmation of normal cortisol diurnal secretion levels, and resumption of normal hypothalamic-pituitary-adrenal function. Recurrence rates have been reported from 3.7 to 9.3%.[25] [36] [38] [39] [41] [42]

KEYWORDS

Cushing's disease - petrosal sinus sampling - transsphenoidal adenomectomy - ACTH - CRH

REFERENCES

  • 1 Burch W. Cushing's disease: a review.  Arch Int Med . 1983;  145 1106-1111
    PubMedGoogle Scholar
  • 2 Graham B S, Tucker W S. Opportunistic infections in endogenous Cushing's syndrome.  Ann Int Med . 1984;  101 334-338
    PubMedGoogle Scholar
  • 3 Higgins T L, Calabrese L H, Sheeler L R. Opportunistic infections in patients with ectopic ACTH-secreting tumors.  Cleve Clin Q . 1982;  49 43-49
    PubMedGoogle Scholar
  • 4 Wurzburger M I, Prelevic G M, Brkic S D. Cushing's syndrome: transitory immune deficiency state?.  Postgrad Med J . 1986;  62 657-659
    CrossrefPubMedGoogle Scholar
  • 5 Small M, Lowe G DO, Forbes C D, Thomson J A. Thromboembolic complications in Cushing's syndrome.  Clin Endo . 1983;  19 503-511
    PubMedGoogle Scholar
  • 6 Chrousos G P, Schulte H M, Oldfiefd E H. The corticotropin-releasing factor stimulation test.  N Engl J Med . 1984;  310 622-626
    PubMedGoogle Scholar
  • 7 Chrousos G P, Schuermeyer T H, Doppman J L. Clinical applications of corticotropin-releasing factor.  Ann Int Med . 1985;  102 344-358
    PubMedGoogle Scholar
  • 8 Cunnah D, Jessop D S, Besser G M, Rees L H. Measurement of circulating corticotropin-releasing factor in man.  J Endocr . 1987;  113 123-131
    PubMedGoogle Scholar
  • 9 Findling J W, Aron D C, Tyrell J B. Selective venous sampling for ACTH in Cushing's syndrome.  Ann Int Med . 1981;  94 647-652
    PubMedGoogle Scholar
  • 10 Friedman R B, Oldfield E H, Nieman L K. Repeat transsphenoidal surgery for Cushing's disease.  J Neurosurg . 1989;  71 520-527
    PubMedGoogle Scholar
  • 11 Fukata J, Nakai Y, Imura H. Human corticotropin-releasing hormone test in normal subjects and patients with hypothalamic, pituitary or adrenocortical disorders.  Endocrinol Jpn . 1988;  35 491-502
    PubMedGoogle Scholar
  • 12 Howlett T A, Drury P L, Perry L. Diagnosis and management of ACTH-dependent Cushing's syndrome: comparison of the features in ectopic and pituitary ACTH production.  Clin Endo . 1986;  24 699-713
    CrossrefPubMedGoogle Scholar
  • 13 Landolt A M, Valvanis A, Girard J, Eberle A N. Corticotropin-releasing factor test used with bilateral, simultaneous inferior petrosal sinus blood-sampling for the diagnosis of pituitary-dependent Cushing's disease.  Clin Endo . 1986;  25 687-696
    PubMedGoogle Scholar
  • 14 Liddle G W. Tests of pituitary-adrenal suppressibility in the diagnosis of Cushing's syndrome.  J Clin Endocrinol Metab . 1960;  20 1539-1560
    PubMedGoogle Scholar
  • 15 Ludecke D K. Intraoperative measurement of adrenocorticotrophic hormone in peripituitary blood in Cushing's disease.  Neurosurg . 1989;  24 201-205
    PubMedGoogle Scholar
  • 16 Manni A, Latshaw R F, Page R, Santen R J. Simultaneous bilateral venous sampling for adrenocorticotropin in pituitary-dependent Cushing's disease: evidence for lateralization of pituitary venous drainage.  J Clin Endocrinol Metab . 1983;  57 1070-1073
    PubMedGoogle Scholar
  • 17 Nieman L K, Chrousos G P, Oldfield E H. The ovine corticotropin-releasing hormone stimulation test and the dexamethasone suppression test in the differential diagnosis of Cushing's syndrome.  Ann Int Med . 1986;  105 862-867
    PubMedGoogle Scholar
  • 18 Oldfield E H, Chrousos G P, Schulte H M. Preoperative lateralization of ACTH-secreting pituitary microadenomas by bilateral and simultaneous inferior petrosal venous sinus sampling.  N Engl J Med . 1985;  312 98-103
    PubMedGoogle Scholar
  • 19 Orth D N. The old and the new in Cushing's syndrome.  N Engl J Med . 1984;  310 649-651
    PubMedGoogle Scholar
  • 20 Schrell U, Fahlbusch R, Buchfelder M. Corticotropin-releasing hormone stimulation test before and after transsphenoidal selective microadenomectomy in 30 patients with Cushing's disease.  J Clin Endocrinol Metab . 1987;  64 1150-1159
    PubMedGoogle Scholar
  • 21 Zovickian J, Oldfield E H, Doppman J L. Usefulness of inferior petrosal sinus venous endocrine markers in Cushing's disease.  J Neurosurg . 1988;  68 205-210
    PubMedGoogle Scholar
  • 22 Findling J W, Tyrell J B. Occult ectopic secretion of corticotropin.  Am J Med . 1986;  146 929-933
    CrossrefPubMedGoogle Scholar
  • 23 Schteingart D E, Lloyd R V, Akil H. Cushing's syndrome secondary to ectopic corticotropin-releasing hormone-adrenocorticotropin secretion.  J Clin Endocrinol Metab . 1986;  63 770-775
    CrossrefPubMedGoogle Scholar
  • 24 Lloyd R V, Chandler W F, McKeever P E, Schteingart D E. The spectrum of ACTH-producing pituitary lesions.  Am J Surg Path . 1986;  10 618-626
    PubMedGoogle Scholar
  • 25 Nakane R, Kuwayama A, Watanabe M. Long-term results of transsphenoidal adenomectomy in patients with Cushing's disease.  Neurosurg . 1987;  21 218-222
    PubMedGoogle Scholar
  • 26 Chandler W F, Schteingart D E, Lloyd R V. Surgical treatment of Cushing's disease.  J Neurosurg . 1987;  66 204-212
    PubMedGoogle Scholar
  • 27 Burrow G N, Wortzman G, Rewcastle N B. Microadenopmas of the pituitary and abnormal sellar tomograms in an unselected autopsy series.  N Engl J Med . 1981;  304 156-158
    CrossrefPubMedGoogle Scholar
  • 28 Jackson L S, Savolaine E R, Franco-Saenz R. False lateralization of a pituitary microadenoma (letter).  Ann Int Med . 1988;  108 767-768
    PubMedGoogle Scholar
  • 29 Swearingen B, Biller B M, Barker II G F. Long-term mortality after transsphenoidal surgery for Cushing disease.  Ann Intern Med . 1999;  130 821-824
    CrossrefPubMedGoogle Scholar
  • 30 Watson J C, Shawker T H, Nieman L K, DeVroom H L, Doppman J L, Oldfield E H. Localization of pituitary adenomas by using intraoperative ultrasound in patients with Cushing's disease and no demonstrable pituitary tumor on magnetic resonance imaging.  J Neurosurg . 1998;  89 927-932
    CrossrefPubMedGoogle Scholar
  • 31 Kurosaki M, Luedecke D K, Knappe U J, Flitsch J, Saeger W. The value of intraoperative cytology during transsphenoidal surgery for ACTH-secreting microadenoma.  Acta Neurochir . 2000;  142 865-870
    CrossrefPubMedGoogle Scholar
  • 32 Kaltsas G A, Giannulis M G, Newell-Price J D. A critical analysis of the value of simultaneous inferior petrosal sinus sampling in Cushing's disease and the occult ectopic adrenocorticotropin syndrome.  J Clin Endocrinol Metab . 1999;  84 487-492
    CrossrefPubMedGoogle Scholar
  • 33 McCance D R, Besser M, Atkinson A B. Assessment of cure after transsphenoidal surgery for Cushing's disease.  Clin Endocrinol (Oxf) . 1996;  44 1-6
    CrossrefPubMedGoogle Scholar
  • 34 Chee G H, Mathias D B, James R A, Kendall-Taylor P. Transsphenoidal pituitary surgery in Cushing's disease: can we predict outcome?.  Clin Endocrinol (Oxf) . 2001;  54 617-626
    CrossrefPubMedGoogle Scholar
  • 35 Simmons N E, Alden T D, Thorner M O, Laws Jr R E. Serum cortisol response to transsphenoidal surgery for Cushing disease.  J Neurosurg . 2001;  95 1-8
    CrossrefPubMedGoogle Scholar
  • 36 Hardy J. Cushing's disease: 50 years later.  J Can Sci Neurol . 1982;  2 375-380
    PubMedGoogle Scholar
  • 37 Styne D M, Grumback M M, Kaplan S L. Treatment of Cushing's disease in childhood and adolescence by transsphenoidal microadenomectomy.  N Engl J Med . 1984;  310 889-893
    CrossrefPubMedGoogle Scholar
  • 38 Fahlbusch R, Buchfelder M, Muller O A. Transsphenoidal surgery for Cushing's disease.  J Roy Soc Med . 1986;  79 262-269
    PubMedGoogle Scholar
  • 39 Salassa R M, Laws E R, Carpenter P C. Cushing's disease: 50 years later.  Trans Am Clin Climatol Assoc . 1982;  94 122-129
    PubMedGoogle Scholar
  • 40 Guilhaume B, Bertagna X, Thomsen M. Transsphenoidal pituitary surgery for the treatment of Cushing's disease: results in 64 patients and long-term follow-up studies.  J Clin Endocrinol Metab . 1988;  66 1056-1064
    PubMedGoogle Scholar
  • 41 Mampalam T J, Tyrell J B, Wilson C B. Transsphenoidal microsurgery for Cushing's disease.  Ann Int Med . 1988;  109 487-493
    PubMedGoogle Scholar
  • 42 Tindall G T, Herring C J, Clark R V. Cushing's disease: results of transsphenoidal microsurgery with emphasis on surgical failures.  J Neurosurg . 1990;  72 363-369
    PubMedGoogle Scholar
  • 43 Sheehan J M, Vance M L, Sheehan, J P, Ellegala D B, Laws Jr R E. Radiosurgery for Cushing's disease after failed transsphenoidal surgery.  J Neurosurg . 2000;  93 738-742
    CrossrefPubMedGoogle Scholar
  • 44 Sonino N, Zielezny M, Fava G A, Fallo F, Boscaro M. Risk factors and long-term outcome in pituitary-dependent Cushing's disease.  J Clin Endocrinol Metab . 1996;  81 2647-2652
    CrossrefPubMedGoogle Scholar
  • 45 Veldman R G, Frolich M, Pincus S M, Veldhuis J D, Roelfsema F. Apparently complete restoration of normal daily adrenocorticotropin, cortisol, growth hormone, and prolactin secretory dynamics in adults with Cushing's disease after clinically successful transsphenoidal adenomectomy.  J Clin Endocrinol Metab . 2000;  85 4039-4046
    CrossrefPubMedGoogle Scholar
  • 46 Simmons N E, Do H M, Lipper M H, Laws Jr R E. Cerebral atrophy in Cushing's disease.  Surg Neurol . 2000;  53 72-76
    PubMedGoogle Scholar
  • 47 Nishizawa S, Oki Y, Ohta S, Yokota N, Yokoyama T, Uemura K. What can predict postoperative ``endocrinological cure'' in Cushing's disease?.  Neurosurgery . 1999;  45 239-244
    PubMedGoogle Scholar
  • 48 Bochicchio D, Losa M, Buchfelder M. Factors influencing the immediate and late outcome of Cushing's disease treated by transsphenoidal surgery: a retrospective study by the European Cushing's Disease Survey Group.  J Clin Endocrinol Metab . 1995;  80 3114-3120
    CrossrefPubMedGoogle Scholar
  • 49 Trainer P J, Lawrie H S, Verhelst J. Transsphenoidal resection in Cushing's disease: undetectable serum cortisol as the definition of successful treatment.  Clin Endocrinol (Oxf) . 1993;  38 73-78
    CrossrefPubMedGoogle Scholar
  • 50 Ohnishi T, Arita N, Yoshimine T, Mori S. Intracavernous sinus ectopic adrenocorticotropin-secreting tumours causing therapeutic failure in transsphenoidal surgery for Cushing's disease.  Acta Neurochir . 2000;  142 855-864
    CrossrefPubMedGoogle Scholar
  • 50a Dickerman R D, Oldfield E H. Basis of persistent and recurrent Cushing's disease: an analysis based on findings at repeat pituitary surgery. Paper presented at AANS, 2001, Toronto, Ontario, CA. J Neurosurg In: press
    Google Scholar
  • 51 Ram Z, Nieman L K, Cutler Jr B G, Chrousos G P, Doppman J L, Oldfield E H. Early repeat surgery for persistent Cushing's disease.  J Neurosurg . 1994;  80 37-45
    CrossrefPubMedGoogle Scholar
  • 52 Ahmed S R, Shalet S M, Beardwell C G, Sutton M L. Treatment of Cushing's disease with low dose radiation therapy.  Brit Med J . 1984;  289 643-646
    PubMedGoogle Scholar
  • 53 Degerblad M, Rahn T, Bergstrand G, Thoren M. Long-term results of stereotactic radiosurgery to the pituitary gland in Cushing's disease.  Acta Endocrinol (Copenh) . 1986;  112 310-314
    PubMedGoogle Scholar
  • 54 Halberg F E, Sheline G E. Radiotherapy of pituitary tumors.  Endo Metab Clin NA . 1987;  16 667-684
    PubMedGoogle Scholar
  • 55 Jennings A S, Liddle G W, Orth D N. Results of treating childhood Cushing's disease with pituitary irradiation.  N Engl J Med . 1977;  297 958-961
    PubMedGoogle Scholar
  • 56 Sandler L M, Richards N T, Carr D H. Long-term follow-up of patients with Cushing's disease treated by interstitial irradiation.  J Clin Endocrinol Metab . 1987;  65 441-447
    PubMedGoogle Scholar
  • 57 Thoren M, Rahn T, Hallengren B. Treatment of Cushing's disease in childhood and adolescence by stereotactic pituitary irradiation.  Acta Paediatra Scand . 1986;  75 388-395
    PubMedGoogle Scholar
  • 58 Estrada J, Boronat M, Mielgo M. The long-term outcome of pituitary irradiation after unsuccessful transsphenoidal surgery in Cushing's disease.  N Engl J Med . 1997;  336 172-177
    CrossrefPubMedGoogle Scholar
  • 59 Sheehan J M, Lopes M B, Sheehan J P, Ellegala D, Webb K M, Laws Jr R E. Results of transsphenoidal surgery for Cushing's disease in patients with no histologically confirmed tumor.  Neurosurgery . 2000;  47 33-39
    CrossrefPubMedGoogle Scholar
  • 60 Gorden P, Comi R J, Maton P N, Go V LW. Somatostatin and Somatostatin Analogue ( SMS 201-995 ) in treatment of hormone-secreting tumors of the pituitary and gastrointestinal tract and nonneoplastic diseases of the gut.  Ann Int Med . 19889;  110 35-49
    PubMedGoogle Scholar
  • 61 Sonion N, Boscaro M. Medical therapy for Cushing's disease.  Endocrinol Metab Clin N Amer . 1999;  28 211-222
    PubMedGoogle Scholar
  • 62 Hearn P R, Reynolds C L, Johansen K, Woodhouse N JY. Lung carcinoid with Cushing's syndrome: control of serum ACTH and cortisol levels using SMS 201-995.  Clin Endo . 1988;  28 181-185
    PubMedGoogle Scholar
  • 63 Chu J W, Matthias D F, Belanoff J, Schatzberg A, Hoffman A R, Feldman D. Successful long-term treatment of refractory Cushing's disease with high-dose mifepristone (RU 486).  J Clin Endocrinol and Metab . 2001;  86 3568-3573
    PubMedGoogle Scholar
      >